RxDoctor Payments Data

Murray David Schwalb, MD

Urology · Middletown, NYNPI 1851368468

Payments from drug & device makers

$2,749in general payments, 2019–2025

Across 34 payments — averaging $80.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Astellas Pharma US Inc$654
  • Coloplast$239
  • Pfizer$100
  • Johnson & Johnson$90
  • Myriad Genetic Laboratories, Inc.$81
  • plus $108 from 5 others

What the payments were for

  • Travel & lodging$1,11741%
  • Food & beverage$81630%
  • Education$81530%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific9$1,478
Astellas Pharma US Inc8$654
Coloplast3$239
Pfizer2$100
Johnson & Johnson1$90
Myriad Genetic Laboratories, Inc.4$81
Halozyme Inc3$49
Antares Pharma, Inc.1$19
ABC Home Medical Supply, Inc.1$15
Rochester Medical Corporation1$13
Clarus Therapeutics Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,749 in reported general payments places this provider in the 45th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$235,847
Medicare patients
585
Services billed
6,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide40$558,267
OrgovyxRelugolix59$159,429
MyrbetriqMirabegron135$96,978
GemtesaVibegron54$36,818
Tamsulosin Hcl874$13,694
Finasteride740$9,019
NitrofurantoinNitrofurantoin Macrocrystal151$6,056
Potassium Citrate ErPotassium Citrate41$4,932
Tolterodine Tartrate ErTolterodine Tartrate55$4,399
Bethanechol Chloride20$2,654
Oxybutynin Chloride ErOxybutynin Chloride124$2,292
Fesoterodine Fumarate ErFesoterodine Fumarate22$2,043
Alfuzosin Hcl ErAlfuzosin Hcl65$1,747
Desmopressin Acetate27$1,606
Silodosin13$1,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$654$655,245175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 952 urology providers in New York.

Other urology in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →